This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

XOMA 629

XOMA Corporation

Drug Names(s): XMP.629

Description: XOMA 629 is a topical anti-bacterial formulation of a BPI-derived peptide (XMP.629) under development as a possible treatment for acne. XMP.629 is a novel synthetic peptide compound derived from bactericidal/permeability-increasing protein (BPI) -- a human host-defense protein that is part of the body's early lines of defense against invading microorganisms.

XOMA 629 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug